Paydirt
Insider filing · BBIO

Neil Kumar sold $4.1M of BridgeBio Pharma (BBIO)

Executed Sep 4 2025, disclosed Sep 8 2025, 4 days later.

Value, as filed
$4.1M
78,300 sh across 8 lots
Executed
Sep 4 2025
the trade date, as filed
Disclosed
Sep 8 2025
4 days after the trade
Return, 21 sessionsiFrom the disclosed entry session; derived
–
purchases only

Returns are measured on stock purchases only.

The filer
NK Neil Kumar Chief Executive Officer profile →

Neil Kumar (Chief Executive Officer) filed 14 Form 4 reports in the trailing twelve months (0 purchases, 14 sales), most often in BridgeBio Pharma, Inc. (BBIO). The largest single filing was $6.0M of BBIO (80,000 sh across 8 lots, as filed), executed Apr 9.

The name
BBIO BridgeBio Pharma, Inc. BBIO · Healthcare · 74 filings in 24 months ticker →

Healthcare · BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases

More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→
Other filings by Neil Kumar in BBIO
BBIOSALE BridgeBio Pharma, Inc. $602K
8,721 sh × $69.01
Exec Sep 17
Filed Sep 21 · 6:21 PM ET BBIOSALE BridgeBio Pharma, Inc. $3.7M
44,880 sh across 6 lots
Exec Aug 18
Filed Aug 20 · 4:31 PM ET BBIOSALE BridgeBio Pharma, Inc. $5.2M
76,242 sh across 10 lots
Exec Jun 4
Filed Jun 8 · 5:30 PM ET BBIOSALE BridgeBio Pharma, Inc. $1.8M
25,303 sh across 4 lots
Exec May 21
Filed May 26 · 5:30 PM ET BBIOSALE BridgeBio Pharma, Inc. $5.2M
77,201 sh across 8 lots
Exec May 7
Filed May 11 · 5:30 PM ET BBIOSALE BridgeBio Pharma, Inc. $6.0M
80,000 sh across 8 lots
Exec Apr 9
Filed Apr 13 · 5:30 PM ET BBIOSALE BridgeBio Pharma, Inc. $5.5M
79,400 sh across 8 lots
Exec Mar 12
Filed Mar 16 · 5:30 PM ET BBIOSALE BridgeBio Pharma, Inc. $2.0M
27,451 sh across 2 lots
Exec Feb 19
Filed Feb 23 · 5:30 PM ET